LINGO-1 (LRRN6A) (pS596) Antibody

Background

LINGO1 is a transmembrane protein predominantly expressed in the central nervous system (CNS) and is involved in the regulation of neuronal and oligodendrocyte function. Structurally, it contains leucine-rich repeats (LRRs) and immunoglobulin (Ig) domains that facilitate protein-protein interactions. LINGO1 plays a critical role in inhibiting axonal regeneration and myelination by interacting with receptors like Nogo receptor 1 (NgR1) in neuronal signaling pathways. Its overexpression has been implicated in neurodegenerative diseases such as multiple sclerosis (MS) and Parkinson’s disease, where impaired remyelination and axonal repair contribute to disease progression. LINGO1 has emerged as a therapeutic target in CNS disorders, with LINGO1 antagonists showing promise in preclinical studies for promoting remyelination and neural repair. Genetic polymorphisms in LINGO1 have also been associated with susceptibility to essential tremor, highlighting its significance in movement disorders.